Saturday, 30 October 2021 09:43

Anticoagulation news items. Week commencing 25th October 2021

Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial

JAMA Neurology
Post hoc exploratory analysis (n=502) found rivaroxaban was superior to aspirin in reducing the risk of recurrent stroke or systemic embolism among NAVIGATE ESUS participants with left ventricular dysfunction (annualised primary event rates: 2.4% vs 6.5%, respectively).


Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA

New England Journal of Medicine
RCT at 202 centres in China (n=6412) found in Chinese patients with minor ischaemic stroke/TIA who were carriers of CYP2C19 loss-of-function alleles, stroke risk at 90 days was modestly lower with ticagrelor than clopidogrel (6.0 vs. 7.6%; HR 0.77; 95% CI, 0.64 to 0.94; p=0.008).



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: